Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 13 04:00PM ET
12.11
Dollar change
+0.31
Percentage change
2.63
%
Index- P/E- EPS (ttm)-1.36 Insider Own15.59% Shs Outstand28.02M Perf Week2.02%
Market Cap397.37M Forward P/E- EPS next Y-0.11 Insider Trans0.00% Shs Float26.99M Perf Month28.69%
Income-34.12M PEG- EPS next Q-0.02 Inst Own28.30% Short Float5.59% Perf Quarter27.47%
Sales22.64M P/S17.55 EPS this Y72.38% Inst Trans2.46% Short Ratio4.18 Perf Half Y58.72%
Book/sh0.31 P/B39.59 EPS next Y86.52% ROA-86.11% Short Interest1.51M Perf Year273.19%
Cash/sh0.43 P/C28.40 EPS next 5Y15.00% ROE-205.01% 52W Range3.10 - 12.88 Perf YTD191.11%
Dividend Est.- P/FCF- EPS past 5Y64.26% ROI-357.92% 52W High-5.98% Beta0.88
Dividend TTM- Quick Ratio1.03 Sales past 5Y3.79% Gross Margin81.13% 52W Low290.65% ATR (14)0.66
Dividend Ex-Date- Current Ratio1.34 EPS Y/Y TTM59.74% Oper. Margin-118.15% RSI (14)60.66 Volatility5.62% 5.95%
Employees76 Debt/Eq0.36 Sales Y/Y TTM945.91% Profit Margin-150.70% Recom1.00 Target Price21.43
Option/ShortYes / Yes LT Debt/Eq0.11 EPS Q/Q105.06% Payout- Rel Volume0.83 Prev Close11.80
Sales Surprise7.06% EPS Surprise130.00% Sales Q/Q2480.65% EarningsNov 08 BMO Avg Volume360.61K Price12.11
SMA209.48% SMA5016.17% SMA20052.63% Trades Volume300,146 Change2.63%
Date Action Analyst Rating Change Price Target Change
Jun-28-24Initiated Craig Hallum Buy $18
May-14-24Initiated Stephens Overweight $25
Jul-26-22Resumed Canaccord Genuity Buy $17
Dec-10-21Initiated H.C. Wainwright Buy $25
Mar-09-21Initiated Canaccord Genuity Buy $24
Jan-05-21Initiated BTIG Research Buy $23
Jun-01-20Initiated Laidlaw Buy $19
Dec-02-24 08:30AM
Nov-09-24 04:00PM
Nov-08-24 08:00AM
Nov-01-24 04:01PM
Oct-25-24 08:30AM
08:30AM Loading…
Oct-17-24 08:30AM
Sep-20-24 04:01PM
Sep-16-24 08:30AM
Aug-28-24 04:01PM
04:01PM
Aug-27-24 08:30AM
Aug-26-24 04:01PM
Aug-20-24 08:30AM
Aug-12-24 04:01PM
Aug-05-24 08:59PM
04:01PM Loading…
04:01PM
08:30AM
Jul-30-24 04:01PM
Jul-22-24 04:01PM
Jul-15-24 12:00PM
Jun-14-24 08:50AM
Jun-03-24 09:55AM
May-28-24 09:30AM
May-17-24 09:55AM
May-15-24 08:50AM
03:02AM
May-14-24 11:52AM
07:30AM
May-07-24 08:30AM
May-06-24 09:00AM
05:15PM Loading…
May-03-24 05:15PM
Apr-23-24 09:55AM
Apr-05-24 09:55AM
Apr-04-24 08:35AM
Apr-02-24 12:00PM
Mar-27-24 11:50AM
Mar-26-24 11:52AM
09:12AM
08:40AM
07:30AM
Mar-22-24 02:43PM
Mar-20-24 08:15AM
Mar-19-24 09:00AM
Mar-18-24 05:20PM
Mar-15-24 08:20AM
Mar-08-24 05:00PM
09:00AM
Feb-22-24 05:00PM
Feb-16-24 05:00PM
Jan-31-24 08:00AM
Jan-23-24 08:00AM
Jan-16-24 08:00AM
Jan-12-24 05:00PM
Dec-15-23 01:02PM
Dec-07-23 09:00AM
Nov-15-23 05:00PM
Nov-13-23 04:05PM
Nov-06-23 04:30PM
Oct-16-23 08:30AM
Oct-10-23 08:30AM
Oct-03-23 08:30AM
Sep-27-23 04:05PM
Sep-14-23 09:59AM
Sep-11-23 08:00AM
Sep-05-23 04:00PM
Sep-01-23 02:07PM
Aug-29-23 08:00AM
Aug-14-23 09:10PM
Aug-12-23 09:02AM
Aug-09-23 05:33PM
Aug-03-23 08:30AM
Jun-21-23 04:10PM
Jun-20-23 08:30AM
Jun-07-23 04:10PM
May-12-23 08:00AM
May-09-23 09:00AM
May-03-23 08:30AM
Apr-03-23 04:30PM
Mar-29-23 09:41PM
Mar-27-23 03:15PM
08:20AM
08:15AM
08:10AM
Feb-16-23 08:30AM
Feb-14-23 08:49AM
Jan-30-23 08:30AM
Jan-17-23 08:00AM
Dec-16-22 04:15PM
Dec-13-22 08:30AM
Dec-08-22 08:30AM
Dec-05-22 09:00AM
Nov-09-22 04:15PM
Nov-08-22 08:00AM
Oct-24-22 04:05PM
Sep-01-22 04:15PM
Aug-08-22 07:45AM
Aug-05-22 08:30AM
Jul-27-22 04:30PM
04:15PM
Jul-20-22 04:10PM
Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded in August 1988 and is headquartered in Queensbury, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MICHEL GERARD JCHIEF EXECUTIVE OFFICEROct 22 '24Option Exercise6.0016,66699,996319,334Oct 23 04:17 PM
Aharon GilDirectorMar 19 '24Buy3.7226,882100,0011,069,710Mar 20 08:00 PM
SALAMON STEVEN A JDirectorMar 19 '24Buy3.7226,882100,0011,121,025Mar 20 07:44 PM